P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer

Cancer Letters

Volumn 355, Issue 1, 2014, Pages 54-60

  Shariat, Sheida ^a   Badiee, Ali ^b   Jalali, Seyed Amir ^a   Mansourian, Mercedeh ^b   Yazdani, Mona ^b   Mortazavi, Seyed Alireza ^a   Jaafari, Mahmoud Reza ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; CTL epitope; HER2 neu peptide; MPL Liposome; Peptide vaccine

Indexed keywords

CHOLESTEROL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHOGLYCEROL; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; GAMMA INTERFERON; LIPID; LIPOSOME; MACROGOL 2000; MALEIMIDE; P5 PEPTIDE; PEPTIDE VACCINE; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOLOGICAL ADJUVANT; LIPID A; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONJUGATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG FORMULATION; FEMALE; IMMUNE RESPONSE; INTERFERON PRODUCTION; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; ONCOGENE NEU; PHYSICAL CHEMISTRY; SURVIVAL TIME; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; IMMUNIZATION; IMMUNOLOGY; MEDICINAL CHEMISTRY; METABOLISM; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; FEMALE; IMMUNIZATION SCHEDULE; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; LIPID A; LIPIDS; LIPOSOMES; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR BURDEN;

EID: 84907977212     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.016     Document Type: Article

References (45)

1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013, 342:1432-1433.
2. Hanson H.L., Donermeyer D.L., Ikeda H., White J.M., Shankaran V., Old L.J., et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000, 13:265-276.
3. Matsui K., O'Mara L.A., Allen P.M. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int. Immunol 2003, 15:797-805.
4. Steinman R.M. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol 2012, 30:1-22.
5. Palucka K., Banchereau J. Human dendritic cell subsets in vaccination. Curr. Opin. Immunol 2013, 25:396-402.
6. Parkin J., Cohen B. An overview of the immune system. Lancet 2001, 357:1777-1789.
7. Watson D.S., Endsley A.N., Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 2012, 30:2256-2272.
8. Alving C.R. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods 1991, 140:1-13.
9. Nordly P., Madsen H.B., Nielsen H.M., Foged C. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opin. Drug Deliv 2009, 6:657-672.
10. Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol 1995, 6:495-524.
11. Alving C.R. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 1993, 187:430-446.
12. Casella C.R., Mitchell T.C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci 2008, 65:3231-3240.
13. Vacchelli E., Galluzzi L., Eggermont A., Fridman W.H., Galon J., Sautes-Fridman C., et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012, 1:894-907.
14. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61(Suppl. 2):1-13.
15. Baxevanis C.N., Sotiriadou N.N., Gritzapis A.D., Sotiropoulou P.A., Perez S.A., Cacoullos N.T., et al. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol. Immunother 2006, 55:85-95.
16. Jalali S.A., Sankian M., Tavakkol-Afshari J., Jaafari M.R. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD nanoparticles. Nanomedicine 2012, 8:692-701.
17. Levin A.A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1999, 1489:69-84.
18. Shariat S., Badiee A., Jaafari M.R., Mortazavi S.A. Optimization of a method to prepare liposomes containing HER2/neu- derived peptide as a vaccine delivery system for breast cancer. Iran. J. Pharm. Res 2014, 13:15-25.
19. Harmon P., Cabral-Lilly D., Reed R.A., Maurio F.P., Franklin J.C., Janoff A. The release and detection of endotoxin from liposomes. Anal. Biochem 1997, 250:139-146.
20. Bartlett G.R. Phosphorus assay in column chromatography. J. Biol. Chem 1959, 234:466-468.
21. Lichtenfels R., Biddison W.E., Schulz H., Vogt A.B., Martin R. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J. Immunol. Methods 1994, 172:227-239.
22. Huang Z., Jaafari M.R., Szoka F.C. Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery. Angew. Chem. Int. Ed. Engl 2009, 48:4146-4149.
23. Schluep T., Hwang J., Cheng J., Heidel J.D., Bartlett D.W., Hollister B., et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res 2006, 12:1606-1614.
24. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol 2010, 10:787-796.
25. Hale A.H. H-2 antigens incorporated into phospholipid vesicles elicit specific allogeneic cytotoxic T lymphocytes. Cell. Immunol 1980, 55:328-341.
26. Raphael L., Tom B.H. Liposome facilitated xenogeneic approach for studying human colon cancer immunity: carrier and adjuvant effect of liposomes. Clin. Exp. Immunol 1984, 55:1-13.
27. Steinman R.M., Bonifaz L., Fujii S., Liu K., Bonnyay D., Yamazaki S., et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv. Exp. Med. Biol 2005, 560:83-97.
28. Reddy R., Zhou F., Huang L., Carbone F., Bevan M., Rouse B.T. pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. J. Immunol. Methods 1991, 141:157-163.
29. Nair S., Zhou F., Reddy R., Huang L., Rouse B.T. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J. Exp. Med 1992, 175:609-612.
30. Chang J.S., Choi M.J., Cheong H.S., Kim K. Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. Vaccine 2001, 19:3608-3614.
31. Luo L., Li Y., Chang J.S., Cho S.Y., Kim T.Y., Choi M.J., et al. Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120. Virology 1998, 240:316-325.
32. Siegel D.P., Epand R.M. The mechanism of lamellar-to-inverted hexagonal phase transitions in phosphatidylethanolamine: implications for membrane fusion mechanisms. Biophys. J. 1997, 73:3089-3111.
33. Connor J., Yatvin M.B., Huang L. pH-sensitive liposomes: acid-induced liposome fusion. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:1715-1718.
34. Düzgünes N., Straubinger R.M., Baldwin P.A., Friend D.S., Papahadjopoulos D. Proton-induced fusion of oleic acid-phosphatidylethanolamine liposomes. Biochemistry 1985, 24:3091-3098.
35. Marciani D.J. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today 2003, 8:934-943.
36. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol 2007, 5:505-517.
37. Schijns V.E., Lavelle E.C. Trends in vaccine adjuvants. Expert Rev. Vaccines 2011, 10:539-550.
38. Li W.M., Dragowska W.H., Bally M.B., Schutze-Redelmeier M.P. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 2003, 21:3319-3329.
39. Disis M.L., Grabstein K.H., Sleath P.R., Cheever M.A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res 1999, 5:1289-1297.
40. Knutson K.L., Schiffman K., Disis M.L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest 2001, 107:477-484.
41. Crotty S., Ahmed R. Immunological memory in humans. Semin. Immunol 2004, 16:197-203.
42. Gao F.G., Khammanivong V., Liu W.J., Leggatt G.R., Frazer I.H., Fernando G.J. Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 2002, 62:6438-6441.
43. Baldridge J.R., McGowan P., Evans J.T., Cluff C., Mossman S., Johnson D., et al. Taking a Toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther 2004, 4:1129-1138.
44. De Becker G., Moulin V., Pajak B., Bruck C., Francotte M., Thiriart C., et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol 2000, 12:807-815.
45. Mazumder S., Maji M., Ali N. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. PLoS Negl. Trop. Dis 2011, 5. e1429.